Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (31-40 of 175) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|October 21, 2004
Pneumococcemia as the presenting feature of multiple myelomaDaniel B Costa, Byol Shin, Dennis L Cooper
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2016
Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung AdenocarcinomaMeghan Shea, Mark S Huberman, Daniel B Costa
JAAD Case Reports|April 7, 2016
Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycyclineChen Amy Chen, Daniel B Costa, Peggy A Wu
Translational Cancer Research|October 18, 2018
Targeting <i>ROS1</i> rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsKartik Sehgal, Rushad Patell, Deepa Rangachari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markersSamuel J Klempner, David W Cohen, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 27, 2019
Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung CancerAndreas Varkaris, Kartik Sehgal, Deepa Rangachari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancerDaniel B Costa, J Anthony Parker, Susan T Schumer
Translational Cancer Research|February 20, 2025
How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020sJulia M Berg, Toshiki A Kobayashi, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2017
Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted TherapiesMary Linton B Peters, Daniel B Costa, Deepa Rangachari
Translational Cancer Research|February 4, 2022
In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancerPoorva Bindal, Page Widick, Daniel B Costa, et al.
Pageof 18

Showing results (31-40 of 175) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|October 21, 2004
Pneumococcemia as the presenting feature of multiple myelomaDaniel B Costa, Byol Shin, Dennis L Cooper
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2016
Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung AdenocarcinomaMeghan Shea, Mark S Huberman, Daniel B Costa
JAAD Case Reports|April 7, 2016
Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycyclineChen Amy Chen, Daniel B Costa, Peggy A Wu
Translational Cancer Research|October 18, 2018
Targeting <i>ROS1</i> rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsKartik Sehgal, Rushad Patell, Deepa Rangachari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markersSamuel J Klempner, David W Cohen, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 27, 2019
Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung CancerAndreas Varkaris, Kartik Sehgal, Deepa Rangachari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancerDaniel B Costa, J Anthony Parker, Susan T Schumer
Translational Cancer Research|February 20, 2025
How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020sJulia M Berg, Toshiki A Kobayashi, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2017
Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted TherapiesMary Linton B Peters, Daniel B Costa, Deepa Rangachari
Translational Cancer Research|February 4, 2022
In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancerPoorva Bindal, Page Widick, Daniel B Costa, et al.
Pageof 18